首页> 外国专利> Fcrh5 Antibodies (anti receptor translocation associated with immunoglobulin Superfamily and Immunoconjugates) and Methods of use

Fcrh5 Antibodies (anti receptor translocation associated with immunoglobulin Superfamily and Immunoconjugates) and Methods of use

机译:Fcrh5抗体(与免疫球蛋白超家族和免疫缀合物相关的抗受体易位)和使用方法

摘要

This application relates to compositions useful for the treatment of Hematopoietic tumor in mammals and to methods using these compositions for the same.Claim 1: an Antibody anti fcrh5 comprises (a) at least one HVR Sequence selected from the group consisting of: (i) HVR L1 - that includes the sequence kasqdvstava (SEQ ID no: 26), (ii) HVR - L2 sasyryt (which comprises the sequence SEQ ID no: 27) (iii), which comprises the secuenci HVR - L3 To qqhfssprt (SEQ ID no: 28), (iv) HVR - H1 gftfssyavs (which comprises the sequence SEQ ID no: 35),(V) - H2 HVR atissggsltfildsvr (which comprises the sequence SEQ ID no: 36), (VI) HVR - H3 pipdyyaldy (which comprises the sequence SEQ ID no: 37); and (b) at least one variant of HVR, where the variation of HVR includes Modification of at least one residue the sequence described In SEQ ID no: 26, 2 7, 28, 35, 36 and 37.
机译:本申请涉及可用于治疗哺乳动物中的造血肿瘤的组合物及其使用该组合物的方法。权利要求1:一种抗体抗fcrh5包含(a)至少一种选自以下的HVR序列:(i) HVR L1-包含序列kasqdvstava(SEQ ID no:26),(ii)HVR-L2 sasyryt(其包含序列SEQ ID no:27)(iii),其包含安全性HVR-L3至qqhfssprt(SEQ ID编号:28),(iv)HVR-H1 gftfssyavs(包含序列SEQ ID no:35),(V)-H2 HVR atissggsltfildsvr(包含序列SEQ ID no:36),(VI)HVR-H3 pipdyyaldy (其包含序列SEQ ID no:37); (b)HVR的至少一种变体,其中HVR的变体包括对至少一个残基的修饰,所述残基的序列为SEQ ID No:26、2、7、28、35、36和37中所述。

著录项

  • 公开/公告号AR076029A1

    专利类型

  • 公开/公告日2011-05-11

    原文格式PDF

  • 申请/专利权人 GENENTECH INC.;

    申请/专利号AR2010P101079

  • 发明设计人

    申请日2010-03-31

  • 分类号C07K16/28;C07K19/00;C12N15/13;C12N5/20;G01N33/574;A61K39/395;A61P35/02;

  • 国家 AR

  • 入库时间 2022-08-21 18:07:25

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号